The role of inflammation, humoral and cell mediated autoimmunity in the pathogenesis of atherosclerosis

Swiss Medical Weekly

Volumn 138, Issue 37-38, 2008, Pages 534-539

  Pereira, Ivanio Alves ^a,c   Borba, Eduardo Ferreira ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c NONE   (Brazil)

Author keywords

Atherosclerosis; Autoantibodies; Autoimmunity; Cellular immunity; Inflammation

Indexed keywords

ANTIBIOTIC AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; BETA2 GLYCOPROTEIN 1 ANTIBODY; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 60; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; OSTEOPROTEGERIN; PHOSPHOLIPASE A2; PHOSPHOLIPID ANTIBODY; PREGNANCY ASSOCIATED PLASMA PROTEIN A; TUMOR NECROSIS FACTOR;

ACUTE HEART INFARCTION; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNITY; BACTERIAL INFECTION; CELL ACTIVITY; CELLULAR IMMUNITY; CELLULAR IMMUNODEFICIENCY; CEREBROVASCULAR ACCIDENT; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; EXPERIMENTAL MODEL; FOAM CELL; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOTHERAPY; INFLAMMATION; METABOLIC SYNDROME X; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; RISK FACTOR; SUBENDOTHELIUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; TH1 CELL; TH2 CELL; THORAX PAIN; VASCULAR ENDOTHELIUM;

EID: 52749097001     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (88)

1. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-9.
2. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-74.
3. Wick G, Knoflach M, Xu Q. Autoimmune and inflammatory mechanisms in atherosclerosis. Ann Rev Immunol. 2004;22:361-403.
4. Badr K, Wainwright. Inflammation in the cardiovascular system: here, there and everywhere. Curr Opin Pharmacol. 2004;4:107-9.
5. Doria A, Sherer Y, Meroni PL, Shoenfeld Y. Inflammation and accelerated atherosclerosis: Basic mechanisms. Rheum Dis N Am. 2005;31:355-62.
6. Paoletti R, Gotto AM, Hajjar DP. Inflammation in atherosclerosis and implications for the therapy. Circulation. 2004; 109(suppl.III): III-20-III-26.
7. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-82.
8. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med. 1999;340:115-26.
9. Li JJ, Fang CH. Atheroscleritis is a more rational term for the pathological entity currently known as atherosclerosis. Med Hypotheses. 2004;63:100-2.
10. Fichtischerer S, Heeschen C, Zeiher A. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol. 2004;4:124-31.
11. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation. 2004;109(suppl.II):II-2-II-10.
12. Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis. Update and therapeutic implications. Circulation. 2007;116:1832-44.
13. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep. 2005;7:140-7.
14. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol. 2002;13:461-70.
15. Bretherton KN, Day AJ, Skinner SL. Effect of hypertension on the entry of 125 I-labeled low density lipoprotein into the aortic intima in normal-fed rabbits. Atherosclerosis. 1976;24:99-106.
16. Gerly R, Schillaci G, Giordano A, et al. T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. Circulation. 2004;109:2744-8.
17. Emeson EE, Shen ML, Bell CG, et al. Inhibition of atherosclerosis in CD4T-cell depleted and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am J Pathol. 1996;149:675-85.
18. Zhou X, Nicoletti A, Elhage R, et al. Transfer of CD4+ cells agravates atherosclerosis in immunodeficient, apolipoprotein E knockout mice. Circulation. 2000;102:2919-22.
19. Sherer Y, Shoenfeld Y. Atherosclerosis: is atherosclerosis a cellular or humoral mediated auto-immune disease? Ann Rheum Dis. 2002;61:97-9.
20. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, Hansson GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145(1):33-43.
21. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;508-19.
22. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998;98:731-3.
23. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet. 1998;351:88-92.
24. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin 6 and the risk of future myocardial infarction among apparently healthy men. Circulation. 2000;101:1767-72.
25. Hurt-Camejo E, Paredes S, Masaa L, Carnejo Sartipy P, Rosengren B, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 2001;44:2761-7.
26. Zhang R, Brennan ML, FU X, et al. Associated between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-42.
27. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Keinecke JW, Libby P Macrophage myeloperoxidase regulation by macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-91.
28. Eiserich JP, Baldus S, Brennan ML, et al. Myeloperoxidase, a leukocyte-derived vascular NO oxidase. Science. 2002;296:2391-4.
29. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-604.
30. Bayes-Genis A, Conover CA, Overgaard MT, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;1022-9.
31. Qin QP, Laitinen P, Majamaa-Voltti K, et al. Release patterns of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc J. 2002;36:358-61.
32. Lund J, Qin QP, Ilva T, Petterson K, Voipio-Pulkki LM, Porela P, Pulkki K. Circulating pregnancy-associated plasma protein A predicts outcome in patients with coronary syndrome but no troponin I elevation. Circulation. 2003;108:1924-6.
33. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-19.
34. Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mouse develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-8.
35. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-6.
36. Malyankar UM, Scatena M, Suchland KL, et al. Osteoprotegerin is a alpha vbeta 3-induced, NF-Kappa B-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-62.
37. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003;88:1024-8.
38. Schoppet M, Preissner KT, Hofbauer LC Rank ligand and osteoprotegerin. Paracrine regulators of bone metabolism and vascular function. Arterioscl Thromb Vasc Biol. 2002;22:549-53.
39. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-7.
40. Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297(2):169-76.
41. George J, Afek A, Gilburd B, et al. Atherosclerosis in LDL-receptor knockout mice is accelerated by immunization anticardiolipin antibodies. Lupus. 1997;6:723-9.
42. Afek A, George J, Shoenfeld Y, et al. Enhancement of atherosclerosis in beta2-glycoprotein1-immunized apolipoprotein E-deficient mice. Pathobiology. 1999;67:19-25.
43. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Throm. 1994;14:32-40.
44. Salonen JT, Yla Herttuala S Yamamoto R, Butler S, Korpela H, Salonen R, et al. Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-7.
45. Ryan M, Owens D, Kilbride B, Collins P, Johson A, Tomkin GH. Antibodies to oxidized lipoproteins and their relationship to myocardial infarction. Q J Med. 1998;91:411-5.
46. Palinski W, Witztum JL. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J Intern Med. 2000;247:371-80.
47. Bergmark C, Wu R, De Faire U. et al. Patients with early onset of peripheral vascular disease have high levels of autoantibodies against oxidized low-density lipoproteins. Arterioscler Thromb Vasc Biol. 1995;15:441-5.
48. Wick G, Perschinka H, Millonig G. Atherosclerosis as an autoimmune disease: an update. Trends Immunol. 2001;22:665-9.
49. Mehta TA, Greenman J, Ettelaie C, et al. Heat shock proteins in vascular disease - A review. Eur J Endovasc Surg. 2005;29:395-402.
50. Lamb DJ, El-Sankary W, Ferns GAA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis. 2002;167:177-85.
51. Benagiano M, D'Elios MM, Amedei A, et al. Human 60-KDa Heat Schock Protein is a target autoantigen of T Cells derived from atherosclerotic plaques. J Immunol. 2005;174:6509-17.
52. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shok protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and metalloproteinase expression. Circulation. 1998;98(4):300-7.
53. Ghayour-Mobarhan M, Lamb DJ, Lovell DP, et al. Plasma antibody titres to heat shock proteins-60, -65 and -70: Their relationship to coronary risk factors in dyslipidaemic patients and healthy individuals. Scand J Clin Lab Invest. 2005;65:601-13.
54. Xu Q, Willeit J, Marosi M, et al. Association of serum antibodies to heat shock-protein 65 with carotid atherosclerosis. Lancet. 1993;341:256-9.
55. Hoppichler F, Lehleitner M, Tragweger C, et al. Changes of serum antibodies to heat-shock protein 65 in coronary heart disease and acute myocardial infarction. Atherosclerosis. 1996;126:333-8.
56. Mukherjee M, De Benedictis C, Jewitt D, Kakkar W. Association of antibodies to heat-shock protein-65 with percutaneous transluminal coronary angioplasty and subsequent restenosis. Thromb Haemost. 1996;75:258-60.
57. Hoshida S, Nishino M, Tanouchi J, et al. Acute Chlamydia pneumoniae infection with acute coronary syndrome. Atherosclerosis. 2005;183:109-12.
58. Huittinen T, Leinonen M, Tenkanen L, et. Al. Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predcting coronary risk. Arterioscler Thromb Vasc Biol. 2002;22:431-7.
59. Mayr M, Meltzer B, Kiechl S, et al. Endotelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation. 1999;99:1560-6.
60. Andraws R, Berger JS, Brown D. Effects of antibiotic therapy on outcomes of patients with coronary artery disease. JAMA. 2005;293:2641-7.
61. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol. 13:486-9.
62. Gharavi AE, Sammaritano L.R, Wen J, Elkon, E.B. Induction of antiphospholipid antibodies by immunization with beta2-GP 1 (apolipoprotein H). J Clin Invest. 1992;90:1105-9.
63. Shoenfeld Y, Harats D, George J. Atherosclerosis and the anti-phospholipid syndrome: a link unravelled? Lupus. 1998;7(suppl):140-3.
64. Matsuura E, Kobayashi K, Tabuchi M, Lopes LR. Accelerated atheroma in the antiphospholipid syndrome. Rheum Dis Clin North Am. 2006;32:537-51.
65. Angelini L, Ravelli A, Carporali R, Rumi V, et al. High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia. Pediatrics. 1994;94:500-3.
66. Chakravarty KK, Al-Hillawi AH, Byron MA, Durkin CJ. Anticardiolipin antibody associated ischemic strokes in eldery patiens without system lupus erythematosus. Age Ageing. 1990;19:114-8.
67. Kushner MJ. Prospective study of anticardiolipin antibodies in stroke. Stroke. 1990;21:295-8.
68. Hess DC, Krauss J, Adams R, Nicholas FT, Zhary DL, Rountree HA. Anticardiolipin antibodies: a study of frequency in TIA and stroke. Neurology. 1991;41:525-8.
69. Nagaraja D, Cristopher R, Manjari T. Anticardiolipin antibodies in ischemic stroke in the young: Indian experience. J Neurol Sci. 1997;150:137-42.
70. Tuhrim S, Rand JH, WU X, et al. Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke. 1999;30:1561-5.
71. Brey RL, Abott RD, Curb D, et al. Beta2-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke. 2001;32:1701-6.
72. Ames PR, Margarita A, Delgado AJ, Tommasino C, Iannacone L, Brancaccio V Anticardiolipin amtibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopatic antiphospholipid antibodies. Lupus. 2002;11:208-14.
73. Harats D, George J. Beta2-glycoprotein 1 and atherosclerosis. Curr Opin Lipidol. 2001;12:543-6.
74. George J, Harats D, Gilburd B, et al. Immunolocalization of Beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation. 1999;99:2227-30.
75. George J, Harats D, Gilburd B, et al. Adoptive transfer of Beta-2-glycoprotein-I reactive lymphocyte enhances early atherosclerosis in LDL receptor-deficient mice. Circulation. 2000;102:1822-7.
76. Meroni PL, Raschi E, Camera M, Testoni C, Khamashta MS, Temoli E. Fluvastatin inhibits the activation of endotelial cells induced by antiphospholipid antibodies in vitro. Arthritis Rheum. 2000;43(suppl.):115.
77. Lopez LR, Simpson DF, Hurley BL, Matsuura E. OxLDL/B2GP1 Complexes and autoantibodies in patients with systemic lupus erythematosus, systemic sclerosis, and antiphospholipid syndrome. Pathogenic implications for vascular involvement. Ann N Y Acad Sci. 2005;1051:313-22.
78. Horkko S, Miller E, Dudl E, et al. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996;98:815-25.
79. George J, Yacov N, Breitbart E, et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with-beta2-glycoprotein I. Cardiovasc Res. 2004;62:603-9.
80. Chen WH, Liu JS. An unusual increase of blood anti-beta2-glycoprotein I antibody but not antiphospholipid antibody in cerebral ischemia: a case report. Angiology. 2001;52:149-54.
81. Farsi A, Domeneghetti MP, Fedi S, Capanni M, Giustu B, Marcucci R, et al. High prevalence of anti-beta2-glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity. 1999;30:93-8.
82. Staub HL, Norman GL, Crowter T, da Cunha VR, Polanczyk A, Bohn JM, Fernandes JG, Chahade WH von Muhlen CA. Antibodies to the atherosclerosis plaque components beta2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia. Arq Neuropsiquiatr. 2003;61:757-63.
83. Ranzolin A, Bohn JM, Norman GL, Manenti E, Bodanese LC, von Mullen CA, et al. Anti-beta2-glycoprotein I antibodies as risk factors for acute myocardial infarction. Arq Bras Cardiol. 2004;83:141-4.
84. FranCk M, Staub HL, Petraco JB, Norman GL, Lassen AJ, Schiavo N, et al. Autoantibodies to the atheroma component beta2-glycoprotein I and risk of peripheral artery disease. Angiology. 2007;58:295-302.
85. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis. A population-based study. Arthritis Rheum. 2005;52:722-32.
86. Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J. Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins. Curr Med Chem. 2007;14(2):243-8.
87. Kwak B, Mulhaupt F, Myit S, March F. Statins as a newly recognized type of immunomodulator. Nature Med. 2000;1399-402.
88. Shah PK, Chyu KY, Fredrikson GN, Nilsson J. Immuno\\\modulation of atherosclerosis with a vaccine. Nat Clin Pract Cardiovasc Med. 2005;639-46.